Inferior Outcomes in Acute Lymphoblastic Leukemia With Translocation (14;18)
Clinical Lymphoma Myeloma and Leukemia · 2025
DOI: 10.1016/j.clml.2025.03.010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2025. Verfasst von Diane Habib und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX. Hauptthemen laut MEDLINE: Translocation, Genetic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Chromosomes, Human, Pair 14, Chromosomes, Human, Pair 18. Die Arbeit nennt 8 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Institutes of Health, National Cancer Institute.
Abstract (Originalsprache)
INTRODUCTION: The (14;18)(q32;q21) chromosomal translocation leading to IGH::BCL2 rearrangement, has been rarely described in B-cell acute lymphoblastic leukemia (B-ALL), mainly in association with MYC rearrangement. The outcome of B-ALL harboring t(14;18)(q32;q21) without MYC rearrangement remains unknown. METHODS: We retrospectively reviewed 2778 cases of B-ALL treated at our institution and identified those harboring a t(14;18)(q32;q21) by karyotype. Cases with concomitant MYC rearrangement and cases of lymphoma were excluded. Three patients with no MYC rearrangement by karyotype but without further confirmation by Fluorescence In Situ Hybridization (FISH), were included. RESULTS: Five patients were included in this analysis, with a median age of 35 years (range, 19-58); 1 patient had central nervous system involvement at diagnosis. Induction therapy consisted of hyper-CVAD in 3 patients, hyper-CVAD with inotuzumab ozogamicin in 1 patient, and asparaginase-based regimen in 1 patient. Four patients (80%) responded, with a median duration of response of 12.9 months (range, 5.1-32.9); 1 patient had primary refractory disease. None of the patients proceeded to an allogeneic hematopoietic stem cell transplantation (HSCT). Four patients received salvage chemotherapy and eventually progressed and died. One patient received salvage therapy with subcutaneous blinatumomab and achieved complete remission with negative measurable residual disease (MRD) by next-generation sequencing (NGS) after 3 courses of therapy. After a median follow-up of 13.4 months, the 2-year event-free survival and overall survival rates were 20% and 25%, respectively. CONCLUSION: The outcome of B-ALL with t(14;18)(q32;q21) is poor. Incorporating immune-therapies, chimeric antigen receptor (CAR)-T cell therapy, with or without HSCT, into the treatment regimens, might further improve outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
- Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX.
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address: fhaddad@mdanderson.org.
Förderung
- NCI NIH HHS
- National Institutes of Health
- National Cancer Institute
Zitieren
APA
Habib, D., Jabbour, E., Bataller, A., Sasaki, K., Tang, G., Loghavi, S., Li, S., Senapati, J., Short, N. J., Jain, N., Kantarjian, H., & Haddad, F. G. (2025). Inferior Outcomes in Acute Lymphoblastic Leukemia With Translocation (14;18). Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2025.03.010
Vancouver
Habib D, Jabbour E, Bataller A, Sasaki K, Tang G, Loghavi S, et al. Inferior Outcomes in Acute Lymphoblastic Leukemia With Translocation (14;18). Clinical Lymphoma Myeloma and Leukemia. 2025. doi:10.1016/j.clml.2025.03.010
BibTeX
@article{Habib2025,
author = {Habib, Diane and Jabbour, Elias and Bataller, Alex and Sasaki, Koji and Tang, Guilin and Loghavi, Sanam and Li, Shaoying and Senapati, Jayastu and Short, Nicholas J and Jain, Nitin and Kantarjian, Hagop and Haddad, Fadi G},
title = {Inferior Outcomes in Acute Lymphoblastic Leukemia With Translocation (14;18)},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2025},
doi = {10.1016/j.clml.2025.03.010}
}
EUVIMED